Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07349459
NA

Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Official title: Clinical Study Evaluating Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

Key Details

Gender

FEMALE

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-04-30

Completion Date

2026-08-30

Last Updated

2026-01-16

Healthy Volunteers

No

Interventions

DRUG

Group 1 (Doxorubicin group)

30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

DRUG

Group 2: Vitamin D group

patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks

DRUG

Group 3: melatonin group

patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks

Locations (1)

Tanta University

Tanta, Egypt